3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Recurrence
2
Lymphoma, B-Cell
2
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Neoplasms
1
Liver Neoplasms
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Erectile Dysfunction
1
Carcinoma, Hepatocellular
1
Interventions
durvalumab
13
Bevacizumab
11
Nivolumab
10
tremelimumab
7
pembrolizumab
6
lenvatinib
6
fludarabine
6
Cyclophosphamide
6
atezolizumab
4
Radiosurgery
4
Cisplatin
4
toripalimab
3
relatlimab
3
Magnetic Resonance Imaging
3
Ipilimumab
3
Gemcitabine
3
X-Rays
2
Standard of Care
2
Sorafenib
2
Riluzole
2
Radiotherapy
2
Photons
2
Patient Navigation
2
Lidocaine
2
Hepatectomy
2
Dexamethasone
2
Biopsy
2
trastuzumab deruxtecan
1
tocilizumab
1
tislelizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Liver Neoplasms
×
Cell- and Tissue-Based Therapy
×
1 year
×
Clear all
NCT06084884
2026-05-22
ATHENA
AstraZeneca
Phase 1/2
Active not recruiting
94 enrolled